 CAMBRIDGE, Mass., Aug. 03, 2021 GLOBE NEWSWIRE -- Immuneering Corporation Nasdaq: IMRX, a biopharmaceutical company advancing a robust pipeline of oncology and neuroscience product candidates that are designed to uniquely disrupt cellular signaling dynamics, today announced the closing of its upsized initial public offering of 8,625,000 shares of Class A common stock, including the full exercise by the underwriters of their overallotment option to purchase 1,125,000 shares of Class A common stock, at a public offering price of 15.00 per share, for total gross proceeds of approximately 129.4 million, before deducting underwriting discounts and commissions and estimated offering expenses payable by Immuneering. 